"Texas Retina Associates is Texas’ largest, most experienced ophthalmology practice focused specifically on the diagnosis and management of diseases of the retina and vitreous, including macular degeneration and diabetic retinopathy. Training at some of the country’s top medical institutions, all of our physicians completed fellowships in retina care, and many have sub-specialized further to treat even the most challenging retina conditions like uveitis and ocular oncology."

During the past decade, Texas Retina Associates conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Retina Associates" #1 collaborator was "National Eye Institute (NEI)" with 17 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "National Institutes of Health (NIH)" with 5 trials as a collaborator, "Allergan" with 4 trials as a collaborator and "Regeneron Pharmaceuticals" with 4 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Texas Retina Associates" are "Diabetic Macular Edema" (11 trials), "Diabetic Retinopathy" (6 trials), "Proliferative Diabetic Retinopathy" (4 trials), "Vitreous Hemorrhage" (2 trials) and "Age Related Macular Degeneration" (1 trials). Many other conditions were trialed in "Texas Retina Associates" in a lesser frequency.

Most popular intervention types in "Texas Retina Associates" are "Drug" (16 trials), "Procedure" (9 trials), "Other" (3 trials), "Behavioral" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (2 trials), "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials), "Prompt aflibercept" (2 trials) and "Ranibizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Texas Retina Associates" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Texas Retina Associates". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Texas Retina Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Texas Retina Associates, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".